Published online Dec 21, 2017. doi: 10.3748/wjg.v23.i47.8277
Peer-review started: October 24, 2017
First decision: November 8, 2017
Revised: November 14, 2017
Accepted: December 4, 2017
Article in press: December 4, 2017
Published online: December 21, 2017
Processing time: 57 Days and 13.5 Hours
Core tip: The number of obese children with nonalcoholic fatty liver with a documented poor outcome is small in spite of the alarming tones used in some papers. The available studies are insufficient to determine whether or not children with nonalcoholic fatty liver have an elevated risk of developing detrimental health conditions. Large-scale longitudinal studies with long-term follow-up of children with nonalcoholic fatty liver are desirable. Since most obese children are not adherent to lifestyle modifications and hypocaloric diets, there is a growing number of studies on pharmacological interventions with the risk of disease mongering, the practice of widening the boundaries of illness in order to expand the markets for treatment. The studies on ancillary pharmacological interventions, in addition to diet and exercise, have been performed in few children with inconclusive and conflicting results. The proposal to the obese patient of an ancillary drug may divert his attention from the diet and exercise.